Study
Molecular profile of IMFT for the identification of potential druggable targets and biomarkers predicting crizotinib response.
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001005419 | Other |
Study Description
The clinical phase II trial EORTC 90101 “CREATE” showed high anti-tumor activity of crizotinib, an ALK/ROS1 inhibitor, in IMFT patients. However, results suggested that other molecular targets in addition to ALK/ROS1 might also contribute to the sensitivity of this kinase inhibitor. We therefore characterized molecular profile of IMFT to identify alterations which could play a role in the response to crizotinib.
Study Datasets 2 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001007803 |
Whole-exome sequencing of IMFT tumor samples from 24 participants in the clinical phase II trial EORTC 90101 “CREATE” (CREATE IMFT cohort)
|
Illumina HiSeq 4000 | 24 |
| EGAD00001007804 |
Whole-genome sequencing of IMFT tumor samples from 24 participants in the clinical phase II trial EORTC 90101 “CREATE” (CREATE IMFT cohort)
|
Illumina HiSeq 4000 | 24 |
Who archives the data?
